AU2002215032A1 - Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof - Google Patents

Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Info

Publication number
AU2002215032A1
AU2002215032A1 AU2002215032A AU1503202A AU2002215032A1 AU 2002215032 A1 AU2002215032 A1 AU 2002215032A1 AU 2002215032 A AU2002215032 A AU 2002215032A AU 1503202 A AU1503202 A AU 1503202A AU 2002215032 A1 AU2002215032 A1 AU 2002215032A1
Authority
AU
Australia
Prior art keywords
inhibition
interaction
active mechanism
oxidized proteins
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215032A
Inventor
Martin Brodde
Beate Kehrel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/en
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/en
Application filed by Individual filed Critical Individual
Publication of AU2002215032A1 publication Critical patent/AU2002215032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
AU2002215032A 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof Abandoned AU2002215032A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10051983.0 2000-10-20
DE10051983A DE10051983A1 (en) 2000-10-20 2000-10-20 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
DE10148624.3 2001-10-02
DE2001148624 DE10148624A1 (en) 2001-10-02 2001-10-02 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
PCT/EP2001/012129 WO2002032445A2 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Publications (1)

Publication Number Publication Date
AU2002215032A1 true AU2002215032A1 (en) 2002-04-29

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215032A Abandoned AU2002215032A1 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Country Status (14)

Country Link
EP (2) EP1994941A3 (en)
JP (1) JP4881535B2 (en)
AP (2) AP2781A (en)
AT (1) ATE406908T1 (en)
AU (1) AU2002215032A1 (en)
CA (1) CA2453140C (en)
CY (1) CY1110418T1 (en)
DE (1) DE50114289D1 (en)
DK (1) DK1328289T3 (en)
ES (1) ES2307662T3 (en)
HK (1) HK1057857A1 (en)
OA (1) OA12431A (en)
PT (1) PT1328289E (en)
WO (1) WO2002032445A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523357C (en) * 2003-04-25 2015-07-14 Hamburger Stiftung Zur Foerderung Von Wissenschaft Und Kultur Treatment of hi-virus infections with oxidised blood proteins
JP5416971B2 (en) 2005-09-16 2014-02-12 コーネル リサーチ ファウンデイション インコーポレイテッド Method for reducing the expression of CD36
JP2010235447A (en) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inhibitory agent for inflammatory cytokine
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
DE102011003936A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Use of proteins / peptides that bind to GRP78 (BIP) in laboratory methods for monitoring platelet aggregation inhibitors
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
CA2067364A1 (en) * 1989-10-06 1991-04-07 Eric T. Fossel Oxidized lipoproteins and methods for their preparation
US5358707A (en) * 1990-01-08 1994-10-25 Schering Corporation Oxidized variants of GM-CSF
AU8305691A (en) * 1990-07-18 1992-02-18 Beth Israel Hospital Association, The Method for treating viral infections using oxidized lipoproteins
EP0728019A4 (en) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Labelled diagnostic compositions and methods of their use
RU2089179C1 (en) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Stimulator of cytokin and hemopoietic factors production and a method of its using
ES2299186T3 (en) 1997-06-20 2008-05-16 LEUVEN RESEARCH & DEVELOPMENT VZW TESTS, ANTIBODIES AND PATTERNS TO DETECT LIPOPROTEINS OF LOW DENSITY OXIDIZED AND MODIFIED WITH MDA.
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU1243500A (en) * 1998-11-06 2000-05-29 Emory University Biomarkers for oxidative stress
DE10045047A1 (en) * 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III

Also Published As

Publication number Publication date
CA2453140A1 (en) 2002-04-25
AP2781A (en) 2013-10-31
EP1328289A2 (en) 2003-07-23
AP2003002795A0 (en) 2003-06-30
CY1110418T1 (en) 2015-04-29
WO2002032445A2 (en) 2002-04-25
JP2004511526A (en) 2004-04-15
AP2009004857A0 (en) 2009-06-30
CA2453140C (en) 2016-01-05
DK1328289T3 (en) 2008-12-15
DE50114289D1 (en) 2008-10-16
ATE406908T1 (en) 2008-09-15
EP1994941A2 (en) 2008-11-26
EP1328289B1 (en) 2008-09-03
ES2307662T3 (en) 2008-12-01
JP4881535B2 (en) 2012-02-22
PT1328289E (en) 2008-12-10
HK1057857A1 (en) 2004-04-23
AP2034A (en) 2009-08-28
OA12431A (en) 2006-04-19
WO2002032445A3 (en) 2003-04-17
EP1994941A3 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
AU2001267475A1 (en) Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof
HK1019774A1 (en) Etching composition and use thereof.
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU6340899A (en) Oxime derivatives and the use thereof as latent acids
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
MXPA02003174A (en) Novel combination of loteprednol and antihistamines.
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU1037900A (en) Magnetic bearing and its use
AU6196299A (en) Preparations containing fine-particulate inorganic oxides
AU2002225247A1 (en) The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof
AU4843500A (en) Destructible surfactants and uses thereof
AUPQ429399A0 (en) Oxidized apolipoproteins and methods of use
AU2841801A (en) Triazolotriazinones and the use thereof
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2001275450A1 (en) Bismuth compounds for the treatment and prevention of mucositis
AU2002215032A1 (en) Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
AU4301100A (en) Isolated peptide of the horny layer and use thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002224876A1 (en) Isolated luciferases and the use thereof
AU2001264488A1 (en) Gene expression cassette and its use
AU2000231564A1 (en) Phosphororganic compounds and the use thereof
AU5571799A (en) Angiogenesis inhibitors and uses thereof
AU2001285145A1 (en) Human abc transporter family member and uses thereof
AU2001291962A1 (en) Angiogenic agents and their uses